Evidence map›Paper›PMID 29959819›Full record

ArticleJournal of applied clinical medical physics2018

Safety and benefit of using a virtual bolus during treatment planning for breast cancer treated with arc therapy.

Marguerite Tyran, Agnes Tallet, Michel Resbeut, Marjorie Ferre, Veronique Favrel, Pierre Fau, Laurence Moureau-Zabotto, Julien Darreon, Laurence Gonzague, Ahcene Benkemouche and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of applied clinical medical physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Marguerite TyranDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Agnes TalletDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Michel ResbeutDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Marjorie FerreDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Veronique FavrelDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Pierre FauDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Laurence Moureau-ZabottoDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Julien DarreonDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Laurence GonzagueDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Ahcene BenkemoucheDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Leonel Varela-CagettiDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Naji SalemDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Bertrand FarnaultDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Marie-Aimee AcquavivaDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Hugues MailleuxDepartment of Radiation-Oncology, Institut Paoli-Calmettes, Marseille, France.
Institut Paoli-Calmettes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study evaluates the benefit of a virtual bolus method for volumetric modulated arc therapy (VMAT) plan optimization to compensate breast modifications that may occur during breast treatment.

methodsTen files were replanned with VMAT giving 50 Gy to the breast and 47 Gy to the nodes within 25 fractions. The planning process used a virtual bolus for the first optimization, then the monitors units were reoptimized without bolus, after fixing the segments shapes. Structures and treatment planning were exported on a second scanner (CT) performed during treatment as a consequence to modifications in patient's anatomy. The comparative end-point was clinical target volume's coverage. The first analysis compared the VMAT plans made using the virtual bolus method (VB-VMAT) to the plans without using it (NoVB-VMAT) on the first simulation CT. Then, the same analysis was performed on the second CT. Finally, the level of degradation of target volume coverage between the two CT using VB-VMAT was compared to results using a standard technique of forward-planned multisegment technique (Tan-IMRT).

resultsUsing a virtual bolus for VMAT does not degrade dosimetric results on the first CT. No significant result in favor of the NoVB-VMAT plans was noted. The VB-VMAT method led to significant better dose distribution on a second CT with modified anatomies compared to NoVB-VMAT. The clinical target volume's coverage by 95% (V95%) of the prescribed dose was 98.9% [96.1-99.6] on the second CT for VB-VMAT compared to 92.6% [85.2-97.7] for NoVB-VMAT (P = 0.0002). The degradation of the target volume coverage for VB-VMAT is not worse than for Tan-IMRT: the median differential of V95% between the two CT was 0.9% for VMAT and 0.7% for Tan-IMRT (P = 1).

conclusionThis study confirms the safety and benefit of using a virtual bolus during the VMAT planning process to compensate potential breast shape modifications.

Indexed as

Breast NeoplasmsHumansRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedUnilateral Breast Neoplasmsbreastradiotherapyskin flashvirtual bolusVMAT

Identifiers

PMID29959819
PMCPMC6123145
OpenAlexW2809877996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.